


hCA/VEGFR-2-IN-3

| | |
|--------------------|---|
| Cat. No.: | HY-155760 |
| CAS No.: | 2971782-73-5 |
| Molecular Formula: | C ₂₄ H ₂₈ N ₆ O ₆ S |
| Molecular Weight: | 528.58 |
| Target: | VEGFR; Carbonic Anhydrase |
| Pathway: | Protein Tyrosine Kinase/RTK; Metabolic Enzyme/Protease |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |



BIOLOGICAL ACTIVITY

| | |
|-------------------------------------|--|
| Description | hCA/VEGFR-2-IN-3 (compound 8j) is an indolinonylbenzenesulfonamide and a potential dual inhibitor of cancer-associated hCA IX/XII and VEGFR-2. hCA/VEGFR-2-IN-3 inhibits VEGFR-2 (IC ₅₀ =358 nM), has high binding activity to hCAs with K _i of 4.2 nM (hCA IX), 22.9 nM (hCA II), 25.1 nM (hCA I), 28.0 nM (hCA XII), respectively. hCA/VEGFR-2-IN-3 has antiproliferative activity against VEGFR-2 overexpressing breast cancer cells ^[1] . |
| IC₅₀ & Target | IC ₅₀ : 358 nM (VEGFR-2), 4.2 nM (hCA IX), 22.9 nM (hCA II), 25.1 nM (hCA I), 28.0 nM (hCA XII) ^[1] |
| In Vivo | hCA/VEGFR-2-IN-3 (compound 8j) MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

REFERENCES

[1]. Saied S, et al. Discovery of indolinone-bearing benzenesulfonamides as new dual carbonic anhydrase and VEGFR-2 inhibitors possessing anticancer and pro-apoptotic properties. *Eur J Med Chem.* 2023 Nov 5;259:115707.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA